Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$507.42 USD
+1.08 (0.21%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $507.62 +0.20 (0.04%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$507.42 USD
+1.08 (0.21%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $507.62 +0.20 (0.04%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
Zacks News
Post-Bell Q4 Highlights: Intel, Starbucks & More
by Mark Vickery
We see a fresh new crop of Q4 earnings reports hitting the tape, with INTC and SBUX leading the way.
Will Flagship Impella Drive ABIOMED's (ABMD) Q3 Earnings?
by Zacks Equity Research
ABIOMED (ABMD) is likely to gain from flagship Impella in third-quarter fiscal 2019; positive trends in the CHD markets buoy optimism.
Will Core Renal Care Unit Fuel Baxter's (BAX) Q4 Earnings?
by Zacks Equity Research
Management at Baxter (BAX) expects Renal Care to see growth of 3-4% in 2018.
Can Diagnostic Revenues Fuel PerkinElmer's (PKI) Q4 Earnings?
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter 2018 results are likely to benefit from the Diagnostics Segment's solid performance.
Accuray's (ARAY) Q2 Loss Narrows, Radixact Demand Shoots Up
by Zacks Equity Research
Demand for flagship Radixact & CyberKnife platforms aids Accuray's (ARAY) fiscal Q2 results.
Why Earnings Season Could Be Great for Intuitive Surgical (ISRG)
by Zacks Equity Research
Intuitive Surgical (ISRG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
CONMED (CNMD) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
CONMED's (CNMD) Q4 results get a boost from solid segmental performances.
ISRG, RMD Earnings on Jan 24: Here Are the Key Predictions
by Zacks Equity Research
Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical space.
5 Amazing Earnings Charts
by Tracey Ryniec
It's not easy to beat nearly every quarter for years but these 5 companies have been doing just that.
Ericsson (ERIC) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Ericsson (ERIC) is likely to report higher year-over-year revenues in the fourth quarter of 2018 on the back of healthy growth dynamics.
Factors Expected to Influence Intel's (INTC) Q4 Earnings
by Zacks Equity Research
Intel (INTC) benefits from both data-centric and PC-centric businesses.
Intuitive Surgical Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Intuitive Surgical.
Intuitive Surgical (ISRG) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Intuitive Surgical (ISRG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Intuitive Surgical (ISRG) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Intuitive Surgical (ISRG) have what it takes to be a top stock pick for momentum investors? Let's find out.
The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intuitive Surgical, Illumina, HCA, Elanco Animal and Humana
Will Instruments Fuel Intuitive Surgical (ISRG) Q4 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) top line in the fourth quarter of 2018 is likely to benefit from solid grow that the Instruments and Accessories segment.
5 Great Medical Stocks to Buy Ahead of Q4 Earnings
by Swarup Gupta
A Reuters review of Wall Street Research firms reveals that health care is the most favored of the S&P 500's 11 major sectors.
Intuitive Surgical (ISRG) Stock Moves -0.52%: What You Should Know
by Zacks Equity Research
Intuitive Surgical (ISRG) closed at $502.71 in the latest trading session, marking a -0.52% move from the prior day.
Why the Earnings Surprise Streak Could Continue for Intuitive Surgical (ISRG)
by Zacks Equity Research
Intuitive Surgical (ISRG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights: Morgan Stanley, Intuitive Surgical, Colgate-Palmolive, Keurig Dr Pepper and Prudential Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Morgan Stanley, Intuitive Surgical, Colgate-Palmolive, Keurig Dr Pepper and Prudential Financial
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ISRG) Outperforming Other Medical Stocks This Year?
Stock Market News For Jan 10, 2019
by Zacks Equity Research
Wall Street rallied for the fourth successive day owing to positive developments on the trade front and Fed Chair???s indication of maintaining caution on further interest rate hikes.
Intuitive Surgical (ISRG) Up on Solid Preliminary Q4 Results
by Zacks Equity Research
Intuitive Surgical (ISRG) is likely to gain from solid da Vinci contributions in fourth-quarter 2018.
Top Research Reports for Morgan Stanley, Intuitive Surgical & Colgate-Palmolive
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, Morgan Stanley (MS), Intuitive Surgical, Inc. (ISRG) and Colgate-Palmolive Company (CL).
Intuitive Surgical (ISRG) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Intuitive Surgical (ISRG) closed at $478.44 in the latest trading session, marking a +1.43% move from the prior day.